Exscientia plc (EXAI)
NASDAQ: EXAI · IEX Real-Time Price · USD
5.14
+0.02 (0.39%)
At close: Jul 19, 2024, 4:00 PM
5.27
+0.13 (2.53%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Exscientia Revenue
Exscientia had revenue of $25.14M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $6.78M. In the year 2023, Exscientia had annual revenue of $25.42M.
Revenue (ttm)
$25.14M
Revenue Growth
-19.78%
P/S Ratio
25.82
Revenue / Employee
$52,047
Employees
483
Market Cap
649.15M USD
Revenue Chart
* The company reports in GBP currency but revenue data is shown in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 25.42M | -7.38M | -22.51% |
| Dec 31, 2022 | 32.80M | -3.68M | -10.09% |
| Dec 31, 2021 | 36.48M | 23.23M | 175.32% |
| Dec 31, 2020 | 13.25M | 1.27M | 10.57% |
| Dec 31, 2019 | 11.98M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aveanna Healthcare Holdings | 1.92B |
| Fulgent Genetics | 287.53M |
| Definitive Healthcare | 255.69M |
| Arcturus Therapeutics Holdings | 124.53M |
| UroGen Pharma | 84.30M |
| IGM Biosciences | 2.11M |
EXAI News
- 4 days ago - Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout - Business Wire
- 11 days ago - Orthobond Expands its Board of Directors with Appointment of Eric Major as Chairman - Business Wire
- 12 days ago - Exscientia Launches AWS AI-powered Platform to Advance Drug Discovery - Business Wire
- 26 days ago - Exscientia plc Class Action: Levi & Korsinsky Reminds Exscientia Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 25, 2024 - EXAI - Accesswire
- 26 days ago - Contact Levi & Korsinsky by June 25, 2024 Deadline to Join Class Action Against Exscientia plc(EXAI) - Accesswire
- 26 days ago - Exscientia Plc Investors With Losses Are Encouraged By The Schall Law Firm To Start Communication Be Aware Of The Deadline In This Case - Accesswire
- 26 days ago - Shareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More - Accesswire
- 26 days ago - EXAI Investors Have Opportunity to Lead Exscientia plc Securities Fraud Lawsuit with the Schall Law Firm - Business Wire